ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0171

The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0412

The Association of Obesity with Juvenile Spondyloarthritis

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0098

The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:

(0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0588

The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0731

The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0760

The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0651

The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0207

The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)

(0199–0209) Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0450

The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0671

The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0169

The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment

(0145–0174) Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0125

The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0460

The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0415

The Impact of Social Vulnerability Index Scores in Pediatric Uveitis

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0522

The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].